Breakthrough T1D

Breakthrough T1D Honors Four Researchers With Annual Awards

NEW YORK – October 29, 2026 -- Breakthrough T1D, the global type 1 diabetes (T1D) research and advocacy organization, has presented four awards to researchers whose work spans disease prevention, insulin pump therapy, beta cell biology and large-scale clinical trials. The recipients were recognized at a ceremony in Philadelphia earlier in October 2026.

Chief Scientific Officer Sanjoy Dutta, Ph.D., said the honorees embody the organization's mission "to accelerate research toward cures for type 1 diabetes while improving the lives of those who live with it."

Breakthrough T1D Closes First CRC, Sets 2027 Edition for Washington

Philadelphia – October 13, 2026 -- Breakthrough T1D, formerly JDRF, closed its inaugural Clinical & Research Congress after more than 80 sessions and scheduled the 2027 edition for Washington, D.C., October 15-17, 2027.

The congress ran October 9-11, 2026, in Philadelphia. It brought together clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience and community advocates.

Sessions span immunotherapies, islet cell therapies and AI-driven tools

The program covered endocrinology, discovery science and immunotherapies, and emerging technologies including AI and digital twins. It also addressed islet cell and disease-modifying therapies, and access to care for the type 1 diabetes (T1D) community.

Experts Issue First Global Consensus on Type 1 Diabetes Screening

New York – September 17, 2026 -- A consensus paper published in Diabetologia establishes the first international framework for population-wide screening of type 1 diabetes (T1D), setting concrete age thresholds and testing protocols for clinical adoption.

Nearly 30 global experts define screening ages and intervals

The guidance, convened by Breakthrough T1D and developed by close to 30 international experts, recommends initial autoantibody screening for children aged 2-4 years. Children who test negative should be rescreened at ages 6-8 and again at 10-15, timed to align with routine preventative healthcare visits. Initial positive results require confirmation with a second test before diagnosis is made.